Management of restless legs syndrome in chronic liver disease: A challenge for the correct diagnosis and therapy

Table 7 Results for gabapentin therapy during follow-up of 41 patients

Test (range)	135th day	165th day	205th day
Hamilton rating scalec(0-66)	9.7 ± 0.4	9.7 ± 0.5	10.0 ± 0.7
	(-9.8 ± 0.2; < 0.01)	(-9.8 ± 0.3; < 0.01)	(-9.9 ± 1.2; < 0.01)
PSQI (0-5)	2.7 ± 0.7	2.9 ± 0.3	3.0 ± 0.5
	(+ 0.7 ± 0.2; NS)	(+0.5 ± 0.2; NS)	(+0.6 ± 0.3; NS)
ESS (0-24)	9 9 ± 0.7	9. 5 ± 0.4	12 .7 ± 1.1
	(-0.7 ± 1.0; NS)	(-0.5 ± 0.1; NS)	(-3.3 ± 0.1; < 0.05)
IRSL (0-40)	0-10 (mild) = 21	18	17
	11-20 (moderate) = 14	19	22
	21-30 (severe) = 6	4	2
	31-40 (very severe) = 0	0	0

Within-group analysis was done by comparing results at each day’s visit vs the 45^th day results. ESS: Excessive diurnal sleepiness; IRLS: International RLS severity scoring system; NS: Nonsignificant; PSQI: Depression, sleep quality assessment.